April 2, 2024 - IGC Pharma released positive interim data from its ongoing Phase 2 CALMA trial for agitation in Alzheimer's disease, providing early validation of IGC-AD1's therapeutic promise.

IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the launch of Holiby™, a wellness brand offering scientifically formulated products for immune defense and ...

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.

Read about IGC Pharma Inc (IGC:XASE) stock and today's latest news and financial updates. IGC - IGC Pharma Inc News | Morningstar Morningstar brands and products ...

About IGC Pharma (dba IGC): IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with ...

The best beauty products of June 2025 include Jones Road’s tinted moisturizer, Numbuzin’s salmon sperm serum, and more. Shop beauty editor-approved staples from Amazon, Sephora, and more ...

The IGC forecasts global grain output at 2.313 billion metric tons in the 2024-25 season, up three million tons from May’s estimate. This would be a record high, just above 2023-24’s estimated ...

During the IGC meeting, Indian officials raised concerns over Nepal's import restrictions on dairy products. In response, Nepal agreed to reconsider its position on items with low domestic ...

The International Grains Council (IGC) said on Thursday it has trimmed its forecast for 2024/25 global wheat production driven partly by a diminished outlook for the European Union.

IGC-AD1 is IGC Pharma's investigational cannabinoid-based therapy currently in a Phase 2 multicenter, double-blind, randomized, placebo-controlled study (CALMA) evaluating its safety and efficacy ...

April 2, 2024 - IGC Pharma released positive interim data from its ongoing Phase 2 CALMA trial for agitation in Alzheimer's disease, providing early validation of IGC-AD1's therapeutic promise.

POTOMAC, MARYLAND/ ACCESS Newswire/ June 30, 2025/ IGC Pharma, Inc., a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders ...